
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 22, 2017 (September 18, 2017)

Neuralstem, Inc.
(Exact name of registrant as specified in Charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-33672
(Commission File No.)

52-2007292
(IRS Employee Identification No.)

20271 Goldenrod Lane, 2nd Floor, Germantown, Maryland 20876
(Address of Principal Executive Offices)

(301) 366-4960
(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On September 18, 2017, the board of directors (“Board”) of Neuralstem, Inc. (the “Company”) filled two vacancies in the Board with the appointments of Cristina Csimma, Pharm.D, MHP and Zhuo Zhang. Pursuant to their respective appointments, the Board currently has 7 acting directors. Mr. Zhang has been designated the director of the Series A 4.5% Convertible Preferred Stock (“Series A Stock”) per his appointment by Tianjin Pharmaceuticals Group International Holdings Co., LTD (the sole holder of the Series A Stock). Dr. Csimma and Mr. Zhang will both serve as Class III directors until the Company’s 2020 annual shareholders meeting or until such time as they resign or are removed.

There are no family relationships among Dr. Csimma or Mr. Zhang and any of our executive officers or directors.

As compensation for their services on the Board, Dr. Csimma and Mr. Zhang will participate in the Company’s non-executive board compensation plan as described in the Company’s Current Report on Form 8-K filed on June 27, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 22, 2017

Neuralstem, Inc.

/s/ Richard Daly
By: Richard Daly
Chief Executive Officer